Stryker Corp (SYK) Stock Price & Analysis
Stryker Corp (SYK) rose 4.14% to USD 314.01 as of June 9, 2026 at 22:37 UTC, according to Nexqual real-time market data.
SYK last closed at USD 301.53; the session ranged USD 302.5–315.16 on volume of 2,701,088 shares. Market capitalization is $120.38B, with a 52-week range of USD 281–404.87 (NYQ). Source: Nexqual, June 9, 2026 at 22:37 UTC.
Key Statistics (as of June 9, 2026 at 22:37 UTC)
| Price | USD 314.01 |
|---|---|
| Change | ▲ 4.14% (up) |
| Previous Close | USD 301.53 |
| Open | USD 303.26 |
| Day Range | USD 302.5 – 315.16 |
| 52-Week Range | USD 281 – 404.87 |
| Volume | 2,701,088 shares |
| Market Cap | $120.38B |
| Exchange | NYQ |
Technical Analysis (SYK)
Nexqual's technical model rates SYK "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 22:37 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 52.06 (neutral) |
| vs SMA50 | Below (USD 316.32) |
| MACD | -2.91 (negative) |
Analyst Ratings (SYK)
Wall Street analysts rate SYK "Buy" based on 26 analysts, with a mean price target of USD 389.93 (range USD 315–465), per Nexqual as of June 9, 2026 at 22:37 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 26 |
| Mean Target | USD 389.93 |
| High Target | USD 465 |
| Low Target | USD 315 |
| Buy / Hold / Sell | 21 / 7 / 0 |
Earnings (SYK)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 3.49 |
| Revenue Estimate | $6.58B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.6 vs est 2.98 ▼ miss |
| 2025-12-31 | USD 4.47 vs est 4.4 ▲ beat |
| 2025-09-30 | USD 3.19 vs est 3.13 ▲ beat |
| 2025-06-30 | USD 3.13 vs est 3.07 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
Financials & Fundamentals (SYK)
| Total Revenue | $25.27B |
|---|---|
| Revenue Growth (YoY) | +2.60% |
| Gross Margin | +64.70% |
| Operating Margin | +17.82% |
| Profit Margin | +13.21% |
| ROE | +15.20% |
| Debt / Equity | 66.3 |
| Current Ratio | 2.11 |
| Total Cash | $2.96B |
| Total Debt | $15.23B |
| Free Cash Flow | $4.36B |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
Financial Health Score (SYK)
Nexqual rates Stryker Corp's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:37 UTC.
| Growth | Solid — Revenue +11% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 65%, operating 18% |
| Balance Sheet | Strong — $2.96B cash vs $15.2B debt |
| Cash Flow | Strong — FCF $4.36B, 17% margin |
| Efficiency | Solid — ROE 15%, ROA 7.7% |
Ownership (SYK)
| Insider Ownership | +5.37% |
|---|---|
| Institutional Ownership | +82.36% |
| Shares Outstanding | 383.36M |
| Float | 347.57M |
| Short % of Float | +1.56% |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
Leadership (SYK)
Stryker Corp is led by Kevin A. Lobo (age 60), Chairman & CEO, per Nexqual as of June 9, 2026 at 22:37 UTC.
| Chairman & CEO | Kevin A. Lobo (age 60) |
|---|---|
| President & COO | Spencer S. Stiles (age 48) |
| VP & CFO | Preston W. Wells (age 48) |
| Group President of Global Quality & Operations | Viju S. Menon (age 57) |
| Group President of MedSurg & Neurotechnology | J. Andrew Pierce (age 51) |
Major Backers & Investors (SYK)
Notable institutional backers of Stryker Corp include Greenleaf Trust, JPMorgan, Price (T.Rowe) Associates Inc, according to Nexqual as of June 9, 2026 at 22:37 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Greenleaf Trust | 4.16% |
| JPMorgan | 4.07% |
| Price (T.Rowe) Associates Inc | 2.62% |
| Wellington Management | 2.12% |
| Morgan Stanley | 1.64% |
| Fidelity | 1.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 15.78% |
| BlackRock | 8.36% |
| State Street | 5.07% |
| Geode Capital | 2.02% |
Source: Nexqual, June 9, 2026 at 22:37 UTC.
From Stryker Corp's Latest SEC 10-K Filing (filed 2026-02-11)
Key Strengths & Strategy (as disclosed to the SEC)
- Stryker Corporation operates as a medical technology company in the United States and internationally.
- It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.
- The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications.
- The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MDT | Medtronic plc. | USD 81.98 | ▲ 0.38% |
| BDX | Becton, Dickinson and Company | USD 152.04 | ▲ 0.58% |
| TMO | Thermo Fisher Scientific Inc | USD 494.07 | ▲ 4.5% |
| BSX | Boston Scientific Corporation | USD 48.96 | ▲ 0.84% |
| DHR | Danaher Corporation | USD 188.41 | ▲ 2.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:37 UTC. This page is informational and not investment advice.